Basal cell carcinoma treatment market seen reaching $13 billion by 2030

The global basal cell carcinoma treatment market is forecast to rise from $8.87 billion in 2026 to $13.03 billion by 2030, according to The Business Research Company. Growth is being driven by more skin cancer cases, wider use of targeted therapies and a shift toward outpatient and precision dermatology care.

Why it matters: - The market is tied to one of the most common forms of skin cancer, with treatment demand rising as diagnosis rates and care access increase. - The forecast points to a faster-growing segment of oncology and dermatology care, with implications for drug makers, surgeons and diagnostic providers. - The report highlights a shift toward less invasive, more personalized treatment options that could change how basal cell carcinoma is managed.

What happened: - The Business Research Company released its Global Market Report 2026 on basal cell carcinoma treatment. - The report says the market will grow from $8.87 billion in 2026 to $13.03 billion by 2030. - The forecast implies a 10.1% compound annual growth rate through 2030. - The report also says the market rose from $8.13 billion in 2025 to $8.87 billion in 2026, a 9.1% CAGR.

The details: - The report links recent market growth to rising non-melanoma skin cancer cases, stronger awareness of early diagnosis, proven surgical treatments, more dermatology specialty clinics and better access to cancer care. - Basal cell carcinoma is a skin cancer that starts in basal cells, which generate new skin cells. - The disease often appears as a small translucent bump, but presentation can vary. - Treatment strategies focus on removing the tumor while considering tumor type, location, size, patient preferences and the ability to monitor the patient over time. - The report cites January 2023 American Cancer Society data showing about 5.4 million basal and squamous cell skin cancer cases annually in the U.S., affecting about 3.3 million people. - Basal cell carcinoma accounts for roughly 80% of those cases. - North America was the largest regional market in 2025. - Asia-Pacific is projected to be the fastest-growing region during the forecast period. - The report also covers Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, the Middle East and Africa. - The new 2026 report includes market attractiveness scoring, TAM analysis, company scoring matrix graphics and tables, Excel-based forecasting dashboards, market hotspots infographics, key technologies and future trend analysis, and updated graphics and tables. - A free sample report is available here. - The full report is available here.

Between the lines: - The growth outlook suggests demand is shifting beyond traditional surgery toward targeted drugs, outpatient care and precision dermatology. - The report’s emphasis on digital platforms and follow-up care points to a broader move toward longer-term management rather than one-time intervention. - Regional momentum appears strongest where healthcare access and dermatology infrastructure are expanding fastest.

What's next: - The market is expected to keep accelerating as targeted therapies, minimally invasive surgery and diagnostic imaging gain broader use. - Personalized treatment plans and earlier detection should become more important over the forecast period. - Wider adoption of outpatient care may support continued growth through 2030. - The report also expects stronger use of digital tools in dermatological care as the market develops.